Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
|Videos|October 17, 2022
Dr. Broghammer on patient selection for treatment with intracavernosal injections
Author(s)Urology Times staff
Advertisement
Joshua A. Broghammer, MD, discusses the ideal patient population for treatment with intracavernosal injections for erectile dysfunction. Broghammer is an associate professor of Urology at the University of Kansas Medical Center.
Advertisement
Related to this article
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5